 |
|
Current Treatment of Neuromuscular Diseases
Lisa Kokontis, MD;
Ludwig Gutmann, MD
Arch Neurol. 2000;57:939-943.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
The past 20 years have seen marked improvement in treatment of immune-mediated neuromuscular diseases because of (1) better understanding of the various pathogenic processes and (2) research and development of immunotherapies. This review focuses on treatable neuromuscular diseases; amyotrophic lateral sclerosis (ALS) is included because new therapies may alter its course. Table 1 outlines the various immunotherapies most commonly used for treatment of immune-mediated neuromuscular diseases today.
Table appears in full text version.
|
|
|
|
Table 1. Immunotherapies Most Commonly Used for Immune-Mediated Neuromuscular Diseases*
|
|
|
INFLAMMATORY MYOPATHIES
The 3 major inflammatory myopathies—dermatomyositis (DM), polymyositis (PM), and inclusion body myositis—have different pathogenic mechanisms. In DM, there is a complement-dependent humoral attack on unidentified antigens on the endothelial cell. In PM, the endomysial cell infiltrate contains an abundance of cytotoxic CD8 T cells, with invasion of nonnecrotic muscle fibers by these same cells and macrophages. In inclusion body myositis, immunopathologic factors are less well understood, and . . . [Full Text of this Article]
INFLAMMATORY DEMYELINATING POLYNEUROPATHIES
MULTIFOCAL MOTOR NEUROPATHY
MOTOR NEURON DISEASES
MYASTHENIA GRAVIS
LAMBERT-EATON MYASTHENIC SYNDROME
From the Department of Neurology, Robert C. Byrd Health Sciences Center of West Virginia University, Morgantown.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(7):1089-1090.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Lambert-Eaton Myasthenic Syndrome in Children
Tsao et al.
J Child Neurol 2002;17:74-76.
ABSTRACT
|
